United States

People: Dr.Reddy's Laboratories Ltd (RDY.N)

RDY.N on New York Stock Exchange

4:02pm EDT
Change (% chg)

$0.51 (+1.08%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Carter, Bruce 

Dr. Bruce L. A. Carter, Ph.D., is Non-Executive Independent Director of Dr.Reddy's Laboratories Ltd. Dr. Bruce L A Carter joined the Company’s Board in 2008. He was the Chairman of the Board and Chief Executive Officer of ZymoGenetics, Inc. USA. Dr. Carter was appointed Chairman of the Board of ZymoGenetics in April 2005. From April 1998 to January 2009, he served as Chief Executive Officer of ZymoGenetics. Dr. Carter first joined ZymoGenetics in 1986 as Vice President of Research and Development. In 1988, Novo Nordisk acquired ZymoGenetics and, in 1994, Dr. Carter was promoted to Corporate Executive Vice President and Chief Scientific Officer for Novo Nordisk A/S, the then parent company of ZymoGenetics. Dr. Carter led the negotiations that established ZymoGenetics as an independent company from Novo Nordisk in 2000. Dr. Carter held various positions of increasing responsibility at G.D. Searle & Co., Limited. from 1982 to 1986 and was a Lecturer at Trinity College, University of Dublin from 1975 to 1982. Dr. Carter is Executive Chairman of Immune Design Corp, USA, and is also on the Board of Regulus Inc., USA. Dr. Carter received a B.Sc. with Honors in Botany from the University of Nottingham, England, and a Ph.D. in Microbiology from Queen Elizabeth College, University of London.

Basic Compensation

Total Annual Compensation, INR 10,225,000
Restricted Stock Awards, INR --
Long-Term Incentive Plans, INR --
All Other, INR --
Fiscal Year Total, INR 10,225,000

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Satish Reddy


G. Prasad


Saumen Chakraborty


Sripada Chandrasekhar


Abhijit Mukherjee


Amit Biswas

As Of  30 Mar 2014